Many people are doing an end-run around their doctor's office, reaching out to potentially unreliable sources that promise to ...

Bioage's experimental drug, azelaprag, being developed to treat obesity, is a GLP-1 agonist, just as Eli Lilly's Zepbound and Novo Nordisk's Wegovy. Some analysts estimate that the market for these ...

The S&P 500 ended 0.3% lower on Wednesday, Sept. 18, 2024, as the Federal Reserve announced its first interest-rate cut since ...

Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease.

The company shipped some 750 vials of testosterone to customers who had instead ordered tirzepatide, the active ingredient in ...

U.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular ...

Healthcare technology company ResMed 's (NYSE: RMD) stock wasn't quite the picture of health on Wednesday. The shares lost more than 5% of their value on news of an analyst's downgrade and his new, ...

SOMAÍ Pharmaceuticals partners with Georgelle to offer Irish patients a broad range of cannabis-based medicines, expanding ...

“It is not one-size-fits-all, and every medication can have risks and side effects,” Mao added in a university news release. ...

We recently compiled a list of the 10 Best Counter Cyclical and Defensive Stocks to Invest In. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the ...

Overall, recent studies have shown that GLP-1 drugs have led to a 10-20% reduction in body weight and lowered the risk of heart attack, stroke and cardiovascular death by approximately 20%.